ROCKVILLE, Md., June 3, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) has received a $2.5 million payment from Fresenius USA Manufacturing, Inc. (Fresenius) for the successful completion of another milestone under the agreement governing the Company’s 2006 sale of PhosLo(r) (calcium acetate) and the product’s related assets to Fresenius for a total consideration of up to $150 million. This milestone payment was contingent on publication of information related to the CARE-2 (Calcium Acetate Renagel Evaluation-2) Study. The twelve month study, published in the June 2008 edition of the American Journal of Kidney Diseases, demonstrated that when lipid levels are kept constant in both treatment groups, there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel (sevelamer hydrochloride).
